Ask HopeStage to review this study with me
Study ID: NCT05440955. We help you review the study, but cannot decide medical eligibility.
Not Yet RecruitingNCT05440955
tDCS for Cognitive Impairment Associated With Recent-onset Schizophrenia
This study is not yet recruiting. It focuses on schizophrenia and currently lists study information in France.
SchizophreniaOtherFrom 18 Years to 35 Years
Key information made simple
This observational study is following people with Schizophrenia or psychosis to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information. This study may not offer a new treatment, and its main value is helping researchers learn from follow-up information that may improve future care.
Your next step
The official record suggests in-person participation through a research setting, with sites including CHU Grenoble Alpes in La Tronche, CH Alpes-Isère in Saint-Égrève, and CH Le Vinatier in Bron. Participation appears to involve assessments along with scans or samples to help researchers understand patterns more clearly. The main fit is usually matching the main diagnosis. The official record does not list a formal phase, which usually means this is focused more on feasibility, delivery, or support than a standard drug-development stage.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateEstimated: June 1, 2023
- Recruitment status
- Not Yet Recruiting
- Estimated enrollment
- Not clearly listed
- Sponsor
- University Hospital, Grenoble
- Sponsor type
- Hospital / academic medical center
- Study type
- Other
- Intervention type
- Other / unclear
- Study phase
- Not clearly listed
- Locations
- France
- Age range
- From 18 Years to 35 Years
- Official registry ID
- NCT05440955
- Official title
- tDCS for Cognitive Impairment Associated With Recent-onset Schizophrenia
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT05440955. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may help clarify how this condition is measured or understood.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in France.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring brain stimulation for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Why is the study type not clearly categorized?
The study type is not clearly categorized in the public registry. Focus on the objective, required tasks, visits, any intervention, and eligibility criteria, then ask the study team to confirm.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 35 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
The public registry does not clearly describe all participation steps. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What risks or points should I check?
The public registry does not make the main risk category clear. Ask the study team what activities are required, what could feel uncomfortable, how safety is monitored, and what happens if you want to stop. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by University Hospital, Grenoble, which appears to be a hospital or academic medical center. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study has not started recruiting yet. You can check the planned start date and available contacts.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meOther studies you may want to explore next
RecruitingNCT05511363
KarXT for Schizophrenia
This study is recruiting in the United States, in France, in the United Kingdom, .... It is testing KarXT for Schizophrenia.
RecruitingNCT06585787
KarXT for Schizophrenia
This study is recruiting in the United States, in France, in Belgium, .... It is testing KarXT for Schizophrenia.
RecruitingNCT07424404
KarXT and KarX-EC for schizophrenia
This study is recruiting in the United States, in France, in Canada, .... It is testing KarXT and KarX-EC for schizophrenia.